Inner Mongolia Furui Med Sci
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company operates in two segments: pharmaceutical production and sales; and diagnostic equipment R&D, production and sales. The pharmaceutical production and sales segment produces and sells products, such as Fufang Biejiaruangan tablets and shell fat capsules… Read more
Inner Mongolia Furui Med Sci (300049) - Net Assets
Latest net assets as of September 2025: CN¥2.35 Billion CNY
Based on the latest financial reports, Inner Mongolia Furui Med Sci (300049) has net assets worth CN¥2.35 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.21 Billion) and total liabilities (CN¥865.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.35 Billion |
| % of Total Assets | 73.06% |
| Annual Growth Rate | 17.08% |
| 5-Year Change | 31.72% |
| 10-Year Change | 28.92% |
| Growth Volatility | 77.27 |
Inner Mongolia Furui Med Sci - Net Assets Trend (2006–2024)
This chart illustrates how Inner Mongolia Furui Med Sci's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Inner Mongolia Furui Med Sci (2006–2024)
The table below shows the annual net assets of Inner Mongolia Furui Med Sci from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.13 Billion | +15.19% |
| 2023-12-31 | CN¥1.85 Billion | +1.18% |
| 2022-12-31 | CN¥1.83 Billion | +1.11% |
| 2021-12-31 | CN¥1.81 Billion | +11.77% |
| 2020-12-31 | CN¥1.62 Billion | +4.12% |
| 2019-12-31 | CN¥1.55 Billion | +2.60% |
| 2018-12-31 | CN¥1.51 Billion | -21.71% |
| 2017-12-31 | CN¥1.93 Billion | +5.81% |
| 2016-12-31 | CN¥1.83 Billion | +10.60% |
| 2015-12-31 | CN¥1.65 Billion | +80.37% |
| 2014-12-31 | CN¥915.10 Million | +22.25% |
| 2013-12-31 | CN¥748.53 Million | +2.03% |
| 2012-12-31 | CN¥733.64 Million | +4.28% |
| 2011-12-31 | CN¥703.52 Million | +2.34% |
| 2010-12-31 | CN¥687.42 Million | +336.57% |
| 2009-12-31 | CN¥157.46 Million | +12.86% |
| 2008-12-31 | CN¥139.52 Million | +9.20% |
| 2007-12-31 | CN¥127.76 Million | +2.62% |
| 2006-12-31 | CN¥124.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inner Mongolia Furui Med Sci's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1645.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥768.72 Million | 43.98% |
| Common Stock | CN¥266.36 Million | 15.24% |
| Other Comprehensive Income | CN¥244.49 Million | 13.99% |
| Other Components | CN¥468.12 Million | 26.79% |
| Total Equity | CN¥1.75 Billion | 100.00% |
Inner Mongolia Furui Med Sci Competitors by Market Cap
The table below lists competitors of Inner Mongolia Furui Med Sci ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Terravest Capital Inc
TO:TVK
|
$1.53 Billion |
|
Longshine Technology Co Ltd
SHE:300682
|
$1.53 Billion |
|
Teekay Tankers Ltd
NYSE:TNK
|
$1.53 Billion |
|
Buckle Inc
NYSE:BKE
|
$1.53 Billion |
|
Athabasca Oil Corp
PINK:ATHOF
|
$1.53 Billion |
|
Zhefu Holding Group Co Ltd
SHE:002266
|
$1.53 Billion |
|
Piramal Enterprises Limited
NSE:PEL
|
$1.53 Billion |
|
K+S Aktiengesellschaft
F:SDF1
|
$1.53 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inner Mongolia Furui Med Sci's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,547,323,178 to 1,747,683,972, a change of 200,360,794 (12.9%).
- Net income of 113,285,457 contributed positively to equity growth.
- Dividend payments of 2,202,308 reduced retained earnings.
- Other comprehensive income decreased equity by 13,800,413.
- Other factors increased equity by 103,078,058.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥113.29 Million | +6.48% |
| Dividends Paid | CN¥2.20 Million | -0.13% |
| Other Comprehensive Income | CN¥-13.80 Million | -0.79% |
| Other Changes | CN¥103.08 Million | +5.9% |
| Total Change | CN¥- | 12.95% |
Book Value vs Market Value Analysis
This analysis compares Inner Mongolia Furui Med Sci's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 79.39x to 8.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.68 | CN¥54.17 | x |
| 2007-12-31 | CN¥0.69 | CN¥54.17 | x |
| 2008-12-31 | CN¥0.75 | CN¥54.17 | x |
| 2009-12-31 | CN¥0.84 | CN¥54.17 | x |
| 2010-12-31 | CN¥2.79 | CN¥54.17 | x |
| 2011-12-31 | CN¥2.82 | CN¥54.17 | x |
| 2012-12-31 | CN¥2.84 | CN¥54.17 | x |
| 2013-12-31 | CN¥2.91 | CN¥54.17 | x |
| 2014-12-31 | CN¥3.40 | CN¥54.17 | x |
| 2015-12-31 | CN¥5.12 | CN¥54.17 | x |
| 2016-12-31 | CN¥5.56 | CN¥54.17 | x |
| 2017-12-31 | CN¥5.65 | CN¥54.17 | x |
| 2018-12-31 | CN¥4.89 | CN¥54.17 | x |
| 2019-12-31 | CN¥5.15 | CN¥54.17 | x |
| 2020-12-31 | CN¥5.27 | CN¥54.17 | x |
| 2021-12-31 | CN¥5.85 | CN¥54.17 | x |
| 2022-12-31 | CN¥5.87 | CN¥54.17 | x |
| 2023-12-31 | CN¥5.88 | CN¥54.17 | x |
| 2024-12-31 | CN¥6.64 | CN¥54.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inner Mongolia Furui Med Sci utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.48%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.40%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.75x
- Recent ROE (6.48%) is below the historical average (8.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 18.21% | 18.59% | 0.65x | 1.51x | CN¥10.19 Million |
| 2007 | 17.64% | 17.78% | 0.63x | 1.58x | CN¥9.73 Million |
| 2008 | 18.51% | 18.28% | 0.63x | 1.60x | CN¥11.87 Million |
| 2009 | 21.86% | 19.12% | 0.72x | 1.59x | CN¥18.68 Million |
| 2010 | 6.82% | 22.28% | 0.26x | 1.16x | CN¥-21.89 Million |
| 2011 | 7.46% | 17.40% | 0.35x | 1.24x | CN¥-17.86 Million |
| 2012 | 5.81% | 10.09% | 0.44x | 1.31x | CN¥-29.66 Million |
| 2013 | 0.69% | 0.94% | 0.46x | 1.60x | CN¥-66.48 Million |
| 2014 | 10.45% | 13.51% | 0.48x | 1.59x | CN¥3.73 Million |
| 2015 | 6.84% | 15.17% | 0.30x | 1.52x | CN¥-42.42 Million |
| 2016 | 8.28% | 14.64% | 0.34x | 1.65x | CN¥-25.19 Million |
| 2017 | 4.07% | 7.42% | 0.33x | 1.67x | CN¥-89.14 Million |
| 2018 | 2.66% | 4.08% | 0.41x | 1.60x | CN¥-97.78 Million |
| 2019 | 3.29% | 5.22% | 0.37x | 1.71x | CN¥-88.49 Million |
| 2020 | 4.58% | 7.67% | 0.35x | 1.69x | CN¥-73.30 Million |
| 2021 | 6.28% | 10.63% | 0.36x | 1.66x | CN¥-56.49 Million |
| 2022 | 6.33% | 9.70% | 0.40x | 1.63x | CN¥-56.65 Million |
| 2023 | 6.56% | 8.80% | 0.44x | 1.71x | CN¥-53.17 Million |
| 2024 | 6.48% | 8.40% | 0.44x | 1.75x | CN¥-61.48 Million |
Industry Comparison
This section compares Inner Mongolia Furui Med Sci's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inner Mongolia Furui Med Sci (300049) | CN¥2.35 Billion | 18.21% | 0.37x | $1.53 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |